EUVIMEDEUVIMED entdecken
Crossref

Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial

J. Schattenberg, M. Sonderup, W. Spearman, V. Calvaruso, N. Antunes, J. Shu, C. O. Zein, K. V. Kowdley

Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e563-e564

DOI: 10.1055/s-0044-1789634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von J. Schattenberg und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elafibranor, a dual peroxisome proliferator-activated receptor-α/δ agonist, is being investigated in primary biliary cholangitis (PBC). In the phase III ELATIVE trial (NCT04526665), elafibranor efficacy was assessed in patients with PBC with inadequate response or intolerance to ursodeoxycholic acid. PBC is characterised by elevated alkaline phosphatase (ALP) levels. As the disease progresses, total bilirubin (TB) levels increase. ALP and TB have prognostic value and form the basis of several clinical biochemical response criteria.

Aim

The primary endpoint (POISE trial endpoint criteria: ALP

Zitieren

APA

Schattenberg, J., Sonderup, M., Spearman, W., Calvaruso, V., Antunes, N., Shu, J., Zein, C. O., & Kowdley, K. V. (2024). Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial. Zeitschrift für Gastroenterologie, 62(09), e563-e564. https://doi.org/10.1055/s-0044-1789634

Vancouver

Schattenberg J, Sonderup M, Spearman W, Calvaruso V, Antunes N, Shu J, et al. Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial. Zeitschrift für Gastroenterologie. 2024;62(09):e563-e564. doi:10.1055/s-0044-1789634

BibTeX
@article{Schattenberg2024,
  author = {Schattenberg, J. and Sonderup, M. and Spearman, W. and Calvaruso, V. and Antunes, N. and Shu, J. and Zein, C. O. and Kowdley, K. V.},
  title = {Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE trial},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2024},
  volume = {62},
  number = {09},
  pages = {e563--e564},
  doi = {10.1055/s-0044-1789634}
}
Kostenlos starten →